AstraZeneca Advances First-in-Human AZD8359 Study in Metastatic Prostate Cancer

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study.

AstraZeneca is running a first-in-human trial named “Phase I/II Dose Escalation & Dose Optimization Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD8359” in adults with metastatic prostate cancer. The goal is to find safe dose levels, understand how the drug behaves in the body, and see early signs of benefit in a hard-to-treat setting.

The study is testing AZD8359, an experimental antibody-based drug designed to guide T cells toward prostate cancer cells. It aims to improve immune attack on tumors that have spread, potentially adding a new option beyond standard hormone and chemotherapy treatments.

This is an interventional Phase I/II study with patients assigned by randomization in later parts of the trial. The model is sequential and open-label, meaning all participants and doctors know the treatment, with early dose-escalation followed by expansion at selected dose levels to focus on treatment effects.

Key dates show the study was first submitted on 2026-04-08, marking the formal launch of the program. The listing was last updated on 2026-05-20, confirming the trial is active and recruiting, with primary and final completion dates to be set as dose and schedule data emerge.

For investors, the update supports the view that AstraZeneca is pushing deeper into next-generation prostate cancer therapies, complementing its existing oncology portfolio. Positive safety and early efficacy signals from AZD8359 could strengthen sentiment toward AZN, while peers in immuno-oncology and prostate cancer drugs may see pressure if this new approach gains traction.

The AZD8359 trial is currently recruiting and remains ongoing, with further details and future updates available on the ClinicalTrials.gov portal under its registered identifier.

To learn more about GB:AZN’s potential, visit the AstraZeneca plc drug pipeline page.